目的 研究消癌平注射液聯(lián)合注射用培美曲塞二鈉和注射用奧沙利鉑治療晚期肺腺癌的臨床療效。方法 選取2014年11月-2016年11月在阜陽(yáng)市第二人民醫(yī)院治療的晚期或轉(zhuǎn)移性的肺腺癌患者130例，所有患者按照入組順序編號(hào)，采用序列號(hào)隨機(jī)法分為對(duì)照組和治療組，每組各65例。對(duì)照組第1天靜脈滴注注射用培美曲塞二鈉500 mg/m²，滴注時(shí)間大于10 min；且第1天還靜脈滴注注射用奧沙利鉑，500 mg/m²加入到5%葡萄糖溶液250 mL中，滴注時(shí)間2~6 h。治療組在對(duì)照組基礎(chǔ)上靜脈滴注消癌平注射液，40 mL加入到5%葡萄糖250 mL中，1次/d，治療14 d。兩組患者均以21 d為1個(gè)療程，治療2個(gè)療程。觀察兩組的臨床療效，比較兩組的血清腫瘤標(biāo)志物和T淋巴細(xì)胞亞群的變化情況。結(jié)果 治療后，對(duì)照組和治療組的緩解率分別為46.15%、66.15%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05），兩組總有效率比較差異無(wú)統(tǒng)計(jì)學(xué)意義。治療后，對(duì)照組糖類(lèi)抗原125（CA125）和癌胚抗原（CEA）水平下降，治療組神經(jīng)元特異性烯醇化酶（NSE）、CA125和CEA水平下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組NSE和CA125水平明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組CD³⁺、CD⁴⁺和CD⁴⁺/CD⁸⁺明顯降低，而治療組CD³⁺和CD⁴⁺/CD⁸⁺明顯提高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 消癌平注射液聯(lián)合注射用培美曲塞二鈉和注射用奧沙利鉑治療晚期肺腺癌具有較好的臨床療效，可調(diào)節(jié)腫瘤標(biāo)志物，改善T淋巴細(xì)胞亞群水平，具一定的臨床推廣應(yīng)用價(jià)值。

Objective To study the clinical effect of Xiaoaiping Injection combined with Pemetrexed Disodium for injection and Oxaliplatin for injection in treatment of advanced lung adenocarcinoma. Methods Patients (130 cases) with advanced lung adenocarcinoma in No. 2 People's Hospital of Fuyang City from November 2014 to November 2016 were randomly divided into control and treatment groups, and each group had 65 cases. Patients in the control group were iv administered with Pemetrexed Disodium for injection with 500 mg/m² at the first day of treatment, infusion time more than 10 min. And they also were iv administered with Oxaliplatin for injection at the first day of treatment, 500 mg/m² added into 5% glucose solution 250 mL, infusion time 2-6 h. Patients in the treatment group were iv administered with Xiaoaiping Injection on the basis of the control group, 40 mL added into 5% glucose solution 250 mL, once daily, treated for 14 d. Patients in two groups were treated for 2 courses, 21 d as a course. After treatment, the clinical efficacies were evaluated, and tumor marker and T lymphocyte subset in two groups were compared. Results After treatment, the remission rates in the control and treatment groups were 46.15% and 66.15%, respectively, and there was difference between two groups (P<0.05). But there were no differences of clinical efficacy between two groups. After treatment, the levels of CA125 and CEA in the control group were significantly decreased, but the levels of NSE, CA125, and CEA in the treatment group were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of NSE and CA125 in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, CD³⁺, CD⁴⁺, and CD⁴⁺/CD⁸⁺ in the control group were significantly decreased, but CD³⁺ and CD⁴⁺/CD⁸⁺ in the treatment group were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xiaoaiping Injection combined with Pemetrexed Disodium for injection and Oxaliplatin for injection has clinical curative effect in treatment of advanced lung adenocarcinoma, can regulate tumor marker, and improve T lymphocyte subset levels, which has a certain clinical application value.